EL4 Syngeneic Model Overview

The EL4 syngeneic model is a murine lymphoma system derived from C57BL/6 mice and is one of the most widely utilized preclinical models for hematologic malignancy and immuno-oncology research. Originally established as a thymoma, EL4 represents a rapidly proliferating, T-cell–derived lymphoma that grows aggressively in immunocompetent mice and provides a robust platform for evaluating immune modulation, cytotoxic therapies, and adoptive cell transfer.

When implanted subcutaneously or administered intravenously, EL4 cells produce either localized solid tumors or disseminated hematologic disease, depending on the experimental design. The model’s versatility and reproducible growth kinetics make it an essential system for investigating immune checkpoint blockade, cytokine therapies, CAR-T cell efficacy, and T-cell signaling mechanisms in vivo.

Request a Custom Quote for EL4 Syngeneic Model

Biological and Molecular Characteristics

The EL4 cell line originated from a chemically induced thymoma in a C57BL/6 mouse. The tumor cells exhibit a round-to-oval morphology, express T-cell surface markers such as CD3 and Thy1, and lack B-cell markers. EL4 tumors proliferate rapidly and display constitutive activation of NF-κB and MAPK signaling pathways, driving uncontrolled growth and cytokine secretion.

The tumor microenvironment of EL4 is highly immunosuppressive, characterized by elevated expression of PD-L1, TGF-beta, and IL-10, as well as infiltration by regulatory T cells and myeloid-derived suppressor cells. Because of these properties, EL4 has become a benchmark model for studying immune evasion, checkpoint inhibition, and the interaction between malignant T cells and the host immune system.

Parameter	Description
Host strain	C57BL/6 (female, 6–8 weeks)
Tumor origin	Chemically induced thymoma (mouse)
Histological type	T-cell lymphoma
Inoculation route	Subcutaneous or intravenous
Tumor take rate	>95%
Doubling time	Approximately 2–3 days in vivo
Metastatic potential	High in IV models; disseminated lymphoma
Immunophenotype	CD3-positive T-cell tumor; PD-L1 expression
Common applications	Immunotherapy, CAR-T cell studies, cytokine therapy, T-cell biology research

In Vivo Model Development and Tumorigenicity

The EL4 model can be established by subcutaneous or intravenous inoculation of viable tumor cells into immunocompetent C57BL/6 mice. Subcutaneous implantation produces measurable solid tumors suitable for anti-tumor efficacy testing, while intravenous administration results in systemic lymphoma with infiltration of lymphoid organs such as the spleen, liver, and bone marrow. Tumors typically appear within 3–5 days, with rapid progression thereafter.

Because EL4 cells grow aggressively and exhibit robust immune evasion, the model is well suited for testing immune checkpoint inhibitors, cytokine modulators, and adoptive T-cell therapies. It also provides a reliable system for evaluating mechanisms of resistance to immunotherapy and for preclinical screening of agents that restore anti-tumor immunity.

Request a Custom Quote for EL4 Syngeneic Model

Histopathology and Immunohistochemical Profile

Histopathological analysis of EL4 tumors reveals densely packed round to oval lymphoid cells with scant cytoplasm, high mitotic activity, and regions of necrosis. The tumors infiltrate adjacent connective tissue and, in disseminated models, colonize the spleen, liver, and bone marrow. The overall histological pattern mirrors aggressive T-cell lymphoma, with rapid expansion and immune suppression.

Immunohistochemical staining confirms strong expression of CD3 and Thy1, verifying T-cell origin, while Ki-67 staining indicates high proliferative activity. PD-L1 expression is moderate to high, both constitutively and in response to cytokine exposure. Inflammatory infiltrates are limited, with macrophages (F4/80 positive) and few CD8-positive cytotoxic T cells at the periphery. This histopathological and immunophenotypic profile reflects a highly proliferative, immune-evasive lymphoma environment, consistent with human T-cell malignancies.

Preclinical Applications and Drug Response

The EL4 syngeneic model is a cornerstone in preclinical immuno-oncology, widely used for evaluating T-cell–based therapies, checkpoint inhibitors, and cytokine-driven anti-tumor mechanisms. The model has demonstrated responsiveness to agents that enhance T-cell activation, such as IL-2, IFN-gamma, and TNF-alpha, and to checkpoint blockade therapies targeting PD-1 and CTLA-4 when combined with immune adjuvants or radiation.

EL4 has also been extensively used in CAR-T cell studies to test T-cell trafficking, persistence, and cytotoxicity in vivo. Its aggressive growth and defined immune suppression make it suitable for testing strategies that reprogram the tumor microenvironment or enhance antigen-specific T-cell recognition. Because of its reproducibility, immunocompetent context, and well-characterized biology, EL4 remains a leading model for translational studies in lymphoma and T-cell immunotherapy development.

Request This Model

To request the EL4 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for EL4 Syngeneic Model